Addex Regains Nasdaq Listing Compliance
February 09, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 9, 2023 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1
February 06, 2023 01:00 ET
|
Addex Therapeutics
Data to be reviewed by independent interim review committee (IRC) to keep study blinded Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 6, 2023 - Addex...
Addex Provides Corporate Update and Financial Guidance
January 19, 2023 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 19, 2023 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration
December 08, 2022 01:00 ET
|
Addex Therapeutics
Addex to receive USD 1 million in additional research fundingCollaboration continues to advance through drug candidate selection phase Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland,...
Addex Reports Q3 2022 Financial Results and Provides Corporate Update
November 11, 2022 01:00 ET
|
Addex Therapeutics
CHF10.4M ($10.4M) of cash and cash equivalents at September 30, 2022Janssen led ADX71149 Phase 2 study in epilepsy on track to complete part 1 in Q1 2023 Ad Hoc Announcement Pursuant to Art. 53 LR ...
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
November 03, 2022 02:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 3, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022
November 03, 2022 02:00 ET
|
Addex Therapeutics
Geneva, Switzerland, November 3, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today...
Addex Increases Issued Share Capital to Create Treasury Shares
November 01, 2022 02:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 1, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...
Addex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
September 20, 2022 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, September 20, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
August 18, 2022 01:00 ET
|
Addex Therapeutics
CHF8.8M ($9.3M) of cash and cash equivalents at June 30, 2022CHF4.6M equity financing in July extends cash runway into Q2 2023Janssen led ADX71149 Phase 2 study in epilepsy expected to report data in...